Cite
HARVARD Citation
Zhang, R. et al. (2021). Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Cancer medicine. pp. 3165-3176. [Online].